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Abstract. In vivo localized proton magnetic resonance spectroscopy (1H MRS) became a powerful and unique technique to
non-invasively investigate brain metabolism of rodents and humans. The main goal of 1H MRS is the reliable quantification
of concentrations of metabolites (neurochemical profile) in a well-defined region of the brain. The availability of very high
magnetic field strengths combined with the possibility of acquiring spectra at very short echo time have dramatically increased
the number of constituents of the neurochemical profile. The quantification of spectra measured at short echo times is compli-
cated by the presence of macromolecule signals of particular importance at high magnetic fields. An error in the macromolecule
estimation can lead to substantial errors in the obtained neurochemical profile. The purpose of the present review is to overview
methods of high field 1H MRS with a focus on the metabolite quantification, in particular in handling signals of macro-
molecules. Three main approaches of handling signals of macromolecules are described, namely mathematical estimation of
macromolecules, measurement of macromolecules in vivo, and direct acquisition of the in vivo spectrum without the contribution
of macromolecules.
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INTRODUCTION
Over the last decades, in vivo localized proton mag-
netic resonance spectroscopy (1H MRS) became a
powerful and unique technique to non-invasively and
longitudinally investigate brain metabolism of rodents
and humans [1–10]. Proton MRS is one of the most
sensitive NMR techniques due to both high gyromag-
netic ratio and high natural abundance of 1H nuclei.
In addition, nearly all brain metabolites contain pro-
tons, so that an important number of biologically
relevant metabolites can be observed [11]. 1H MRS
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is in principle sensitive enough to ensure an in vivo
detection of brain metabolites at concentration as low
as 0.5 mM. The availability of very high magnetic
field strengths (≥7 T) combined with the possibility of
acquiring spectra at very short echo time (TE) (<10 ms)
have dramatically increased the number of in vivo
detectable brain metabolites, allowing in animal mod-
els and humans the detection of about 20 metabolites
(also called the neurochemical profile). They are mark-
ers of: myelination/cell proliferation (phosphocholine,
glycerophosphocholine, phosphoethanolamine, N-
acetylaspartate (NAA), N-acetylaspartylglutamate),
energy metabolism (glucose, lactate, creatine, phos-
phocreatine, alanine), osmoregulation (taurine, myo-
inositol), neurotransmitter metabolism (glutamate,
glutamine, aspartate, -aminobutyrate, glycine), and
antioxidants (ascorbate, glutathione) [1–9, 12, 13].
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Reliable quantification of low concentration metabo-
lites (ascorbate, glycine) has been previously shown
[14–18]. In addition, brain metabolite changes have
been demonstrated during development [7, 19–23],
reflecting functional and structural evolution and
regional specificity [7, 16, 19, 24]. It has already been
shown that brain metabolite concentrations can vary
depending on the type of pathology. The usefulness
of the neurochemical profile has been demonstrated in
many brain disorders, e.g., in hepatic encephalopathy,
Alzheimer’s, Huntington’s, and Parkinson’s diseases,
acute traumatic brain injury, cancer, dementia, etc. [11,
25–44], to understand underlying metabolic processes
and/or to monitor effect of treatment.
Brain metabolites and macromolecules
Generally, an in vivo 1H MRS spectrum acquired
in the brain contains the contribution of numerous
resonances originating from low-molecular weight
metabolites which are superimposed on signals of
high-molecular weight macromolecules (MM). There
are two types of the MM signals, those given by nuclei
of backbones of macromolecules having severely
restricted mobility, and those given by nuclei of outer
parts of macromolecules or those of smaller macro-
molecules having higher mobility. The nuclei of the
macromolecular backbones have very short T2 relax-
ation times and therefore their signals are difficult to
detect. However, the signals of large MM can contain
useful clinical information in various pathological con-
ditions. Therefore, new experimental schemes, such as
the low excitation pulse angle method, can be help-
ful [45] in measuring these signals. In addition, for
detecting the short T2 signals of large molecules hav-
ing potential clinical relevance, development of new
pulse sequence detecting short T2 signals of large
macromolecules would be useful. The present review
deals with signals of less hindered parts of MM,
which are seen in localized 1H spectra of brain mea-
sured with relatively short TE. Previous studies [4,
46–53] have extensively reported on macromolecular
resonances in brain of animals and humans. These res-
onances have been, in part, assigned to methyl and
methylene resonances of amino acids in cytosolic pro-
teins, such as leucine, isoleucine, valine, threonine,
alanine, lysine, arginine, glutamate, glutamine, and -
methine protons [46]. However, the presence of lipid
resonances cannot be fully excluded [46]. Lipid reso-
nances have been reported in different diseases, i.e.,
in tumors or demyelination [25, 54, 55]. The eval-
uation of lipid resonances is quite difficult in brain
due to potential contamination with extracerebral lipid
containing tissues. Overall, approximately 10 compo-
nents of macromolecular resonances were observed [4,
46–49, 56]: 0.93 ppm (M1), 1.24 ppm (M2), 1.43 ppm
(M3), 1.72 ppm (M4), 2.05 ppm (M5), 2.29 ppm (M6),
3.00 ppm (M7), 3.20 ppm (M8), 3.8–4.0 ppm (M9),
and 4.3 ppm (M10).
The macromolecular resonances have physical
properties different from those of metabolites, allowing
their separate measurement in vivo. The longitudinal
(T1) and transverse (T2) relaxation times of MM are
shorter than those of metabolites [4, 48, 57, 58], due
to their large molecular weight. The significant dif-
ference in T1 relaxation times enables the selective
measurement of MM or metabolites using the inversion
recovery technique (IR) [59]. In addition, the shorter
T2 relaxation times of MM effectively eliminate their
contribution at longer TE. MM are also characterized
by increased linewidths compared to those of metabo-
lites. It should be noted that at high magnetic fields the
largely field-independent linewidths of MM increas-
ingly approach that of metabolites. The MM are further
characterized by a more hindered mobility as well
as diffusivity due to their larger molecular size. A
previous study [60] reported that MM have an appar-
ent diffusion coefficient (ADC) 10–20 times lower
than that of metabolites. This specific property allows
separate measurement of their signals by diffusion
weighting techniques (DW), which are based on atten-
uating the metabolite signal with minimal alteration of
MM [61]. Moreover, MM have extensive scalar cou-
pling patterns among the resonances (∼7 Hz), which
can affect the detection of -aminobutyrate.
Advantages of high magnetic ﬁeld
Several groups have studied the potential advantages
of increasing magnetic field for 1H MRS [1, 2, 6, 8, 13,
48, 62]. An increase in intrinsic signal-to-noise ratio
(SNR) and chemical shift dispersion are the main ben-
efits at high magnetic fields, which are expected to
be useful for low concentrated metabolites, strongly
overlapped metabolites, and for metabolites having
complex J-coupled spectral patterns. The increased
SNR can translate into increased precision of the mea-
surement and quantification or it might be traded off
for reduced voxel size, while still maintaining a rea-
sonable SNR for reliable quantification. It has also
been shown that these benefits lead to an increased
precision of metabolite quantification [1, 2, 8, 62].
Despite these advantages, some factors can inter-
fere and can decrease the quantification precision.
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Resonance frequency of nuclear spins is proportional
to a magnitude of the static magnetic field (B0). When
B0 is spatially inhomogeneous, resonance frequency of
1H nuclei is not the same over the measured volume of
a tissue, which results in broadening spectral lines and
in decreasing spectral resolution and SNR. Magnetic
field inhomogeneities increase with the magnetic field
because magnetic susceptibility differences between
tissues, blood, bone, and air (in Hz) are proportional
to the static magnetic field, thus leading to increased
peak linewidths (in Hz). 1H MRS is technically rather
challenging in rodent brain due to the small size of the
brain, especially if spectra are acquired in a specific
brain region, which, in addition, is located close to the
interface between the diamagnetic tissue and paramag-
netic oxygen in air. The B0 inhomogeneity induced in
the brain by the difference in susceptibility on air/tissue
interface are scaled with B0, and powerful high order
shim systems are necessary to compensate for them.
For relative small volumes selected for localized MRS
powerful first- and second-order shims are typically
sufficient [6, 63–66]. The chemical shift artifact was
shown to be increased due to frequency selective local-
ization. The use of stronger gradients can limit this arti-
fact; however, attention has to be paid to eddy currents.
Finally, the T1 relaxation times have been shown to
increase with magnetic field [48], leading to increased
signal saturation for shorter repletion times (TR). This
can be overcome by increasing TR, which would
increase the total acquisition time or decreasing signal
averaging in the same total acquisition time. However,
the T1 increase of metabolites does not seem to be
important at static magnetic fields beyond 9.4 T [67].
The purpose of the present study is to review
high field 1H MRS techniques of metabolite quan-
tification with the main focus on proper handling
of macromolecular baseline. We describe three main
approaches of handling the MM: 1) Mathematical esti-
mation of macromolecules; 2) Separate measurement
of macromolecules in vivo; and 3) Direct acquisition of
an in vivo spectrum without the contribution of macro-
molecules.
QUANTIFICATION
The main goal of localized in vivo 1H MRS is
the reliable quantification of the concentration of
known metabolites in a well-defined region of the
brain and the extension of the number of quantifi-
able metabolites. Metabolite concentration ratios are
often used as markers of brain metabolite concentration
changes. However, absolute metabolite concentrations
can be more valuable for an accurate interpretation of
molecular mechanism underlining the pathogenesis of
neurological diseases.
Accurate and precise quantification of brain metabo-
lites is challenging and depends on: hardware
performance (RF system and shim system), pulse
sequence design and adjustments (localization, water
suppression, outer volume suppression, shimming, TE,
repetition time, pulse calibrations, etc.), data process-
ing (estimate of the signal amplitude or peak area), and
quantification strategies (conversion into concentra-
tion units). Any misadjustment of the above mentioned
acquisition parameters can affect the spectral quality
leading to unreliable metabolite concentrations (for
more details refer to [12]). Important is the choice of
data processing, since many algorithms depend on user
input which leads to additional inaccuracies. For more
details, see [68–75].
Advantages of high ﬁeld for quantiﬁcation
As already mentioned, measurements at a high mag-
netic field benefit from decreased strong coupling
effects, increased spectral dispersion (increased spec-
tral resolution), and higher SNR (increased sensitivity),
which likely improve quantification precision and
accuracy [1–9, 62]. The increase in SNR is expected
to also be useful for low concentrated metabolites, for
strongly overlapping metabolite peaks, or even for the
metabolites having complex J-coupled spectral pat-
terns. Moreover, acquisition performed at a short TE
enables to obtain high quality spectra with resolved
lines of many metabolites [1–5, 7, 9], thus increasing
the amount of biochemical information.
Despite the aforementioned advantages of high mag-
netic fields, quantification still remains difficult due to
the complexity of the spectra (many resonances, peak
overlap, contribution of macromolecules, and residual
water); the potential presence of distorted lineshapes
(residual eddy currents, field inhomogeneity); and a
variable baseline (MM, lipid signals, distortions due
to insufficient water suppression). Among these factors
which complicate the quantification, the last two can
be in principle eliminated. The distorted lineshapes can
be minimized by the use of optimal shimming [76–79],
eddy currents compensation [80], and also by using dif-
ferent post-processing algorithms [81]. In addition, the
use of well-calibrated localization sequences and outer
volume suppression combined with good water sup-
pression can increase the reproducibility of the baseline
in 1H spectrum.
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Short echo times
Short TE in vivo 1H MRS spectra (TE = 1–20 ms)
contain more information due to minimal J-modulation
distortions of multiplets of coupled spin systems
such as glutamate, glutamine, myo-inositol, glucose,
aspartate, alanine, -aminobutyrate, ascorbate, phos-
phoethanolamine, glycine, and taurine. In addition, the
signal loss due to T2 relaxation is reduced and conse-
quently a more precise quantification is expected. At
high magnetic field, the T2 relaxation times of metabo-
lites are shorter [48, 82, 83]. The measurement of
T2 relaxation times for the J-coupled metabolites is
possible, provided that the signal modulation due to
J-coupling is taken into account [83]. Therefore, acqui-
sitions at short TE and long TR (fully relaxed spectra)
are considered to be a good choice for absolute quan-
tification, since the effects of relaxation are minimized.
Long echo times
On the other hand, at longer TE (above 20 ms), the
number of spectral lines, which can be used for quan-
tification, is reduced due to fast T2 relaxation and the
J-evolution of coupled spin systems. In addition, care
has to be taken regarding the absolute quantification
of long TE spectra, since the signal intensities are no
longer proportional to the metabolite concentrations
and correction factors for the T2 relaxation times have
to be used. It has to be emphasized that the T2 relax-
ation times can be different for individual nuclei within
the same molecule (e.g., T2 relaxation times of the
methyl groups are different from those of the CH2 or
CH groups [83, 84]) and therefore can further compli-
cate the absolute quantification. As a result, in most
in vivo 1H MRS studies, only concentrations of NAA,
creatine + phosphocreatine, choline, and lactate can be
evaluated.
Quantiﬁcation algorithms
To account for the complex spectral pattern of
metabolites, severe overlap of proton signals of brain
metabolites and the presence of low concentrated
metabolites, sophisticated approaches for the spectral
analysis are required. Metabolite concentrations are
usually determined by fitting the measured in vivo
1H MRS spectrum to a linear combination of spectra
of individual metabolites (also called the metabolite
basis set) (Fig. 1), which makes quantification fea-
sible, especially for low concentration metabolites
[85, 86]. The metabolite basis set can be obtained either
by measuring aqueous solutions of pure metabolites
or by quantum mechanics simulations, based on the
density-matrix formalism [87], using published val-
ues of J-coupling constants and chemical shifts [88],
and the relevant acquisition parameters. The measure-
ment of aqueous solutions has to be done under the
same conditions as the measurement of in vivo data
(the same magnetic field, acquisition sequence, tim-
ings, temperature, pH). Any change in the acquisition
of in vivo data has to be taken into account in the
basis set by reacquiring the basis set using the new
acquisition parameters. This process can sometimes be
time demanding. Therefore, quantum mechanic simu-
lations seem to be a faster alternative, but also more
flexible and less expensive. The obtained individual
spectra of each metabolite can be used without any
post-processing [89–92] or they can be first parame-
terized [93] and then used as prior knowledge. The
influence of the simulated and measured basis sets on
the metabolite concentrations using QUEST as a quan-
tification algorithm has been shown to be equivalent
[70], provided that lineshape corrections are taken into
account. The best fitting errors are estimated from the
Crame´r-Rao lower bounds (CRLB) [85, 94], which are
independent of the quantification algorithm and esti-
mated using the assumption that the model function is
correct and complete. Other authors [14] have demon-
strated the impact on the quantification of a missing but
detectable metabolites from the basis set. They used the
case of ascorbate in the analysis of spectra in develop-
ing brain and showed that the quantification of other
metabolites can be systematically affected.
Well-known time and frequency-domain algo-
rithms, based on metabolite basis sets, are currently
used for accurate quantification. The most frequently
used algorithms for proton spectra quantification are
QUEST [89] from jMRUI software working in the
time domain; LCModel [91, 92], working in the fre-
quency domain; AQSES [90], working in time domain;
and TDFD [95], working in both time and frequency
domains. A more detailed description of these algo-
rithms can be found elsewhere [68–75, 89, 90, 93, 95].
Recently, new algorithms have been developed for the
quantification of 2D MRS spectra [96].
HANDLING OF MACROMOLECULE
RESONANCES
As already mentioned, the quantification of short
TE spectra is complicated by the presence of under-
lying broad signals of macromolecules. Reliable
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Fig. 1. The LCModel analysis of a representative 14.1 T spectrum. The measured in vivo spectrum in the rat brain at 14.1 T is shown in (a). The
corresponding LCModel fits using the measured macromolecule spectrum is also displayed in (b). The traces below represent from top to bottom,
measured macromolecules, residual baseline and the difference between the measured and fitted data (also called residue of the quantification).
The fits of the individual metabolites are plotted in (c). Phosphocholine (PCho), glycerophosphocholine (GPC), phosphoethanolamine (PE),
N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), glucose (Glc), lactate (Lac), creatine (Cr), phosphocreatine (PCr), alanine (Ala),
taurine (Tau), myo-inositol (Ins), glutamate (Glu), glutamine (Gln), aspartate (Asp), -aminobutyrate (GABA), glycine (Gly), ascorbate (Asc),
glutathione (GSH).
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quantification of the MM signals in short TE pro-
ton MRS spectra plays a key role in determining the
neurochemical profile [4, 68, 69, 71, 97]. An error
in the macromolecule estimation can lead to substan-
tial errors in the obtained metabolite concentrations as
previously shown [68, 69, 71, 97].
It has already been shown in humans [49] that MM
content and composition can depend on the cerebral
location and age of the subject, while no gender dif-
ferences were found. Similarly, Mader and colleagues
[98] showed that MM concentration is higher in the
cerebellum and motor cortex than in pons or white
matter, presumably due to higher content of gray mat-
ter in these regions. A recent study performed at 7 T
on healthy volunteers [99] revealed a slight variability
in the shape of the MM with a higher concentration
for gray matter compared with white matter in the
spectral regions around 1.5–1.6 ppm and 2.3–2.6 ppm.
Based on the small effects on metabolite concentration
of the gray and white matter macromolecule signals,
the authors [99] concluded that a general in vivo mea-
sured macromolecule spectrum seems sufficient to
ensure a reliable quantification of the metabolites in
the human brain at 7 T. In fact, the same MM spectrum
is commonly used as a part of the basis set in the quan-
tification of spectra from different regions of the brain,
regardless the quantification algorithm. Although the
metabolite profile regionally varies in the rat brain [20],
regional alterations of the MM signal were reported to
be minimal [100, 101], thus a generic experimental
macromolecule spectrum acquired in a fairly big voxel
(e.g., 4 × 4 × 4 mm3 for the rat brain) can be used, pro-
vided that the shim quality is sufficient to allow for a
good spatial resolution. In addition, few studies have
investigated the macromolecular changes with disease
[53, 55, 102, 103]. One group reported that changes in
the macromolecule concentrations can be considered
as disease markers [103].
Accounting for the MM contributions to an in
vivo spectrum can be accomplished mainly by using
three approaches: 1) Mathematical estimation of
macromolecules; 2) Separate measurement of macro-
molecules in vivo; and 3) Direct acquisition of an
in vivo spectrum without the contribution of macro-
molecules. These three main approaches will be
discussed, with the advantages and disadvantages
given for each approach.
Mathematical estimation of macromolecules
When the spectrum of macromolecules is unknown,
it can be mathematically approximated. Two kinds
of approaches can be distinguished: 1) the macro-
molecule spectrum included the model function, and
2) the macromolecule spectrum estimated separately in
a pre-processing step. Note that both procedures pro-
vide a mathematical approximation of the real in vivo
macromolecule spectrum [68, 69, 71, 97].
The macromolecule spectrum approximated by a
mathematical function (a sum of splines, wavelets,
sinusoids or polynomials with adjustable
parameters) and then included in the ﬁt
[90–92, 104].
This approach is commonly used by several algo-
rithms, e.g., LCModel and AQSES. The importance of
the accurate assessment of the macromolecule contri-
butions in quantification of short TE 1H MRS spectra
using LCModel was recently demonstrated [69]. In this
study, two different approaches of estimating macro-
molecule contributions in the quantification step at
14.1 T in the rat brain were compared: mathemati-
cal estimation of macromolecules using splines and
an acquired macromolecule spectrum in vivo. Despite
excellent spectral dispersion at high field, many spec-
tral lines of metabolites have been shown to remain
overlapped among each other as well as with MM sig-
nals. The LCModel quantification using a basis set of
simulated spectra of metabolites combined with the
measured spectrum of MM provided an excellent fit
to the experimental data. The built-in LCModel spline
baselines fitted well the signals of MM, except for the
region close to water resonance at around 4.5 ppm.
However, this smooth approximation of the in vivo
MM did not reproduce completely all features of the
in vivo spectrum of macromolecules. Compared to
the measured MM spectrum, the built-in LCModel
spline baseline was elevated around 2.0 and 4.0 ppm
and lowered around 3.0 and 3.2 ppm, leading to a
statistical significant decrease and an increase of con-
centrations of metabolites resonating in these regions,
respectively (Fig. 2). These results showed that an
experimental estimation of the macromolecule spec-
trum can improve the quality of the fit at high field. The
absence of the measured macromolecule spectrum in
the database leads to a large and unpredictable bias in
concentrations of many metabolites (Fig. 2c). Even at
the highest magnetic fields available for in vivo exper-
iments, spectral overlap of proton signals from brain
metabolites and macromolecules still require an exper-
imental assessment of macromolecular contribution to
the proton spectrum for accurate metabolite quantifi-
cation. Even if the fitted splines reproduce the in vivo
macromolecules very well, it was concluded [69] that
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Fig. 2. A representative 14.1 T spectrum acquired in the rat brain combined with (a) the built-in LCModel spline baseline (the colored lines
represent the spline baselines obtained from five different rats and overlaid in different colors) and (b) the measured in vivo macromolecule
spectrum. c) Quantification results obtained using the spectrum of macromolecules measured in vivo (black bars) and the built-in LCModel
spline baseline (light blues bars).
the measured macromolecular “baseline” represents
additional prior knowledge, which led to a more accu-
rate and reliable quantification, especially important at
higher static magnetic fields.
The macromolecule spectrum separately
estimated in a pre-processing step
This can be achieved by: (a) modeling of the MM
in the frequency domain with wavelets [104, 105] or
in the time-domain using singular value decomposi-
tion [106] and subsequent subtraction; (b) truncation
of initial data points [107]; and (c) ‘Subtract’ [89] or
numerical filter approach [75].
Only few studies at lower magnetic field strengths
of 3 T and 7 T [68, 71, 97] compared the simulated
and experimentally obtained spectra of MM in the
quantification of in vivo proton spectra, e.g., using
the Subtract-QUEST algorithm [89]. In this algorithm,
the macromolecule spectrum is mathematically esti-
mated from the first data-points of the MRS signal.
This approach exploits the fact that the macromolecule
signals decay rapidly due to shorter T2 relaxation
times. Strategic selection of the number of initial
data-points can separate the metabolite part from fast
decaying parts and thus decorrelate metabolite and
nuisance parameters [89]. In the version of Subtract-
QUEST used by [68, 71, 97], the number of data-points
involved was chosen by user in an empirical way such
that the phased real-part of the MM spectrum esti-
mates was positive and the main resonances of the
MM were well identified. When the number of cho-
sen initial data-points was too low, the MM estimates
were underestimated, whereas too many initial data-
points led to an overestimation of the MM estimates.
As for the LCModel quantification using splines, sig-
nificant differences in the calculated concentrations
were obtained when using the mathematical estima-
tion of the MM. Moreover, it was also observed
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that the macromolecule spectrum estimated by
Subtract-QUEST displayed only broader features,
inconsistent with what was actually seen in the mea-
sured spectra.
Mathematical approaches generally exploit the
short T2 relaxation of macromolecules to provide a
mathematical approximation of the real in vivo macro-
molecule spectrum [69, 71, 97, 108]. However at
higher magnetic fields, where the macromolecule spec-
trum is better resolved, additional prior knowledge
is needed to obtain an accurate estimation of the
metabolite concentrations. The main reason of the poor
mathematical estimation of MM at high magnetic fields
is that the largely field-independent linewidths of the
signals of macromolecules increasingly approaches
those of metabolites. Otazo et al. [52] have recently
shown a change in the shape in the macromolecule
spectrum (in the region of 0 ppm to 3.2 ppm) when
increasing the magnetic field strength from 1.5 T to
7 T: at 1.5 T the macromolecule spectrum was charac-
terized by the presence of 4 broad resonances while at
7 T the number of resonances increased to 9.
Despite the problems encountered at a high magnetic
field, mathematical modeling of the MM spectrum may
be sufficient at low magnetic fields because compo-
nents of this spectrum are relatively broad compared to
the linewidths of the metabolite peaks. Overall, a good
mathematical estimation should reproduce well the
features of the in vivo macromolecule spectrum, inde-
pendently of the magnetic field or the quantification
algorithm. A recent study [109] showed that the built-in
spline estimation of MM using LCModel reproduced
well the features of the in vivo measured MM spec-
trum and provided a good approximation of the MM
baseline at 3 T. The experimentally measured MM
baseline and the built-in spline baseline gave a similar
neurochemical profile, however, small but significant
differences in the quantification of some metabolites,
such as 16% for glutamate, were observed. In addi-
tion, the adaptability of the built-in spline baseline
likely allows a more accurate LCModel quantification
especially in pathological cases where the MM can be
specifically altered depending on the studied region
and the stage of the disease. In such a case, using built-
in splines for modeling MM spectrum would largely
eliminate the need to measure the MM baseline in
each patient. The main advantage of the mathematical
approach is a reduction of the total scanning time since
measuring the MM spectrum is not necessary for each
patient. This feature is important for clinical exam-
ination and also during longitudinal/dynamic data
acquisition.
Separate measurement of macromolecules in vivo
The second approach providing the necessary prior
knowledge is based on a separate acquisition of the
in vivo macromolecule spectrum using methods that
exploit the different physical properties of the MM:
short T1 compared with the metabolites or the slower
diffusion.
Several techniques have been proposed to separately
measure the MM spectrum, some of which will be
described.
Inversion-recovery (IR) technique
The IR sequence is considered to be the gold stan-
dard for MM acquisition. In general, for the in vivo
acquisition of the MM, an IR module consisting of a
180◦ RF pulse and an inversion time (TI) is applied
before the localization sequence. The 180◦ RF pulse
inverts the Z magnetization which is being restored
toward the equilibrium value during the TI delay. Due
to the shorter T1 relaxation time of MM compared
to metabolites, metabolites are nulled at a specific
TI, whereas the MM is almost fully recovered. After
the excitation pulse, a “metabolite-nulled spectrum”
is obtained. However, small residuals of peaks of
metabolites are still observed in the metabolite-nulled
spectrum due to variability in longitudinal relaxation
times of metabolites [48, 67]. Thus, knowledge of the
T1 relaxation times of metabolites [48, 67, 82, 110] is
required for identification of these residual metabolite
signals and subsequent removal by post-processing,
typically using HLSVD [111]. In addition, reducing
the repetition time in the IR experiment is beneficial
for the measurement of MM by reducing the effect of
differences in T1 relaxation times of metabolites [8,
112].
Some examples for measuring in vivo MM spec-
trum using the IR technique at ultra-high magnetic
field in rat brain can be found in [2, 4, 69]. For exam-
ple [3], the SPECIAL sequence was extended with a
2-ms nonselective hyperbolic secant inversion pulse
(a bandwidth of 10 kHz) for the in vivo measure-
ment of macromolecule resonances [2, 69]. A series
of IR spectra (TE of 2.8 ms, TR of 2500 ms and 640
averages) were measured with TI of 420, 600, 750,
850, and 1000 ms (Fig. 3). Based on the evolution of
the metabolite intensities over the series of inversion
recovery spectra (changing from negative to positive),
the spectrum at TI = 750 ms and TE = 2.8 ms was taken
as a basis for the spectrum of MM, since it con-
tained the smallest residual metabolite peaks (positive
or negative). Since T1 relaxation times of metabolite
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Fig. 3. a) Coronal view of a rat brain showing a typical position of a volume of interest. b) One series of in vivo spectra acquired at 14.1 T in the
rat brain with different inversion times (TI), ranging from 0 to 1.8 s. c) Estimation of the spectrum of macromolecules based on IR-SPECIAL
spectra using from bottom to top TIs of 420, 600, 750, 850, 1000 ms (TE = 2.8 ms). The signals marked on the figure were identified as metabolite
residuals in the spectrum at long TE (40 ms) and consequently removed by HLSVD. d) The spectrum measured with the inversion time of 750 ms,
TE = 40 ms (bottom) and the final spectrum of macromolecules after removing the residual peaks of metabolites by HLSVD (top). The residual
signal of NAA at 2.7 ppm marked with asterisk in the spectrum is reduced and inverted relative to that in the spectrum (c) due to J-evolution.
resonances are not identical [48, 67], a macromolecule
spectrum with completely suppressed metabolite res-
onances could not be obtained. Therefore, to confirm
the residual metabolite peaks, an inversion recovery
spectrum with the same TI = 750 ms, but with a longer
TE = 40 ms, was acquired (Fig. 3d). In this spectrum
the residual signals of metabolites were still visible
due to longer T2 relaxation times, while the signals of
MM were substantially reduced due to their short T2
relaxation times. The residual peaks of NAA at 2.0 and
2.7 ppm, taurine at 3.4 ppm, total choline at 3.2 ppm,
myo-inositol at 3.6 ppm, and total creatine at 3.9 ppm
identified in the spectrum were then removed from the
macromolecule spectrum using HLSVD. Care has to
be taken when using HLSVD since the user defines
manually in the spectrum the frequency region from
where the signals to be removed without any addi-
tional prior knowledge. Consequently, the metabolite
residuals might not be completely removed as any con-
straints or prior knowledge can be set leading to over-
or under-estimations of MM and baseline distortions
that are likely to affect the metabolite quantification
accuracy. A recent study [101] developed a novel
and more accurate method than HLSVD for removing
residual metabolite signals from the MM spectrum by
including advanced prior knowledge on the metabo-
lite residuals. Constraints were set manually on the
peak frequency, phase, linewidth, and amplitude to
fit the residual metabolite peaks to be removed. The
method was combined with AMARES quantification
algorithm [113].
Multiple inversion-recovery (MIR) technique
As already mentioned, the MM spectrum measured
using single IR always contained residual of metabo-
lites due to their variation in T1 relaxation times.
Consequently, based on the MIR technique proposed
by Dixon et al. [114], it was shown that using double
or multiple inversion recovery sequences the longitu-
dinal magnetization of the metabolites was close to
zero, while the shorter T1 of MM led to greater sig-
nal recovery [48, 56]. This technique is very similar
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to the IR technique mentioned above with the excep-
tion that several IR pulses are used with optimized
time delays between them aiming for a better nulling
of the metabolite residuals. It was reported that this
technique is relatively insensitive to metabolite T1 s
[48, 56]. However, this method has the drawback that
signal intensities in the macromolecule spectrum can
be weighted by T1 relaxation of individual molecular
components, leading to a distorted MM spectrum.
Diffusion weighted spectroscopy (DW MRS)
The MM are ascribed to cytosolic proteins [46, 47]
and hence expected to have a slow self-diffusion con-
stant, which can be assessed using diffusion weighted
and measuring the ADC. Indeed MM have been shown
to have ADCs 10 to 20 times lower than those of
metabolites [60]. Therefore, the use of DW techniques
could improve the MM estimation by attenuating the
metabolites signal without significantly altering that
of MM. The measurement of MM using DW MRS
has been proposed by Kunz et al. [61] in the rat brain.
By combining IR with DW, the authors showed that
the metabolite-nulled spectrum (acquired using only
IR) previously contaminated by residuals attributed
to creatine, myo-inositol, taurine, choline, NAA as
well as glutamine and glutamate peaks, showed sig-
nificant attenuation (approx 50%) of these peaks when
combining IR with DW, while the MM signals were
almost unaffected (Fig. 4). It was thus likely that the
final spectrum obtained was composed of only the
MM signals with metabolite signals reduced to noise
level. The authors concluded that the present tech-
nique improves the state-of-art by determining the MM
signals purely experimentally, eliminating the need
for any post-processing. This technique provides an
excellent assessment of the MM with negligible con-
tamination with residual metabolite peaks.
Saturation-recovery (SR) technique
Hofmann and colleagues [49] have presented a
method based on a series of saturation recovery scans
on a human scanner at 1.5 T, that allowed for the simul-
taneous measurement of the MM and the fully relaxed
metabolites spectrum. Overall, the authors used for
each spectrum N = 16 different saturation time delays,
from 0.4 to 9.0 s. The resulting spectra were mod-
eled point-by-point to a saturation recovery curve of
m (m≤ N–1) components with predefined T1 values.
An arbitrary threshold was chosen (at 500 ms) to sep-
arate metabolites from MM, then with appropriate
weighting of the original SR spectra, fully relaxed
MM and metabolites spectra were calculated without
Fig. 4. DW spectra combined with IR acquired with STEAM
sequence (TE = 8 ms, TM = 20 ms, TR = 2.5 s, TI = 740 ms, 720 aver-
ages). Diffusion gradient were gradually increased, giving b-value
ranging from 0 (a) to 11.8 ms/m2 (d). The difference spectra
between (a) and (d) have a very flat baseline, demonstrating the
insensitivity of macromolecules to diffusion weighting experiment.
Additionally, several metabolite residuals can be identified in the
difference spectra such as creatine (Cr), myo-inositol (Ins), tau-
rine (Tau), N-acetylaspartate (NAA), and glutamine and glutamate
compounds (Glx).
further assumptions. Comparing to the IR technique,
the SR technique was less susceptible to T1 differences.
Consequently, the proposed technique allowed good
separation between MM and metabolites based on T1
differences.
It is widely accepted that the inclusion of the mea-
sured MM spectrum in quantification will lead to
improved reliability and accuracy of metabolite con-
centrations especially at high magnetic fields. For
minimizing intensity of residual peaks of metabo-
lites, parameters of the pulse sequence used for the
measurement of the MM spectrum should be care-
fully adjusted. Identification of the residual peaks of
metabolites is usually based on different physical prop-
erties of macromolecule and metabolite peaks, e.g., on
differences in T1 relaxation times when using the IR
technique. Residual metabolite peaks have to be unam-
biguously identified for their subsequent elimination
using different post-processing techniques. The post-
processing step has to be done carefully; otherwise it
might lead to biased results. Overall, the in vivo mea-
surement of MM can be time demanding, which might
be a limiting factor in some studies, e.g., of patients in
serious conditions.
Once acquired (either by IR, DW, or SR), the MM
spectrum, free of extra cerebral lipids, has then to be
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included in the basis set. As previously mentioned for
the metabolites basis set, the MM spectrum can be han-
dled in two ways: 1) can be added to the basis set just
as any other metabolite. When included in the basis
set, the MM spectrum can be included as a whole [68,
69, 71, 108] or can be first split into separate com-
ponents [53]. The use of individual components of
the MM spectrum can be advantageous when some
resonances of the MM spectrum can be affected by
diseases; however, the degrees of freedom in the mod-
eling will increase, which might reduce the robustness
of the fitting. An alternative approach is to use the
whole macromolecule spectrum in the basis set plus
some macromolecule/lipid peak components [28] in
the regions where the MM and/or lipid signals are
altered by a disease; and 2) can be subtracted from
the in vivo signal [97, 115, 116]. The main advantage
in subtracting the MM signal from the in vivo sig-
nal before quantification is that no correlation between
the MM and the metabolites will exist anymore. How-
ever, this method will lead to an increase in the noise
of the final signal, which will lead to an increase
in CRLB of the calculated metabolite concentrations
[116]. Consequently, it is advantageous to subtract only
the initial macromolecule data-points whose contribu-
tion exceeds the noise level.
Direct acquisition of the in vivo metabolite
spectrum without the contribution of
macromolecules
Several techniques have been proposed to acquire
the metabolite signals without the contributions of
MM.
One of them is the acquisition at long TE. This
approach exploits the fact that the MMs have shorter
T2 than the metabolites. As a result, the acquired spec-
trum at long TE will not contain the MM contributions
anymore. Care has to be taken regarding the abso-
lute quantification of long TE spectra since corrections
for the T2 relaxation times are necessary. However, in
pathologic conditions when the MM or lipids content
is increased, spectra can still be contaminated by the
presence of MM as well as lipids.
The multiple IR technique is generally used for
the acquisition of the MM spectra. However, by
choosing proper time delays between the inversion
pulses and a proper repetition time, this technique can
also be used for the acquisition of the metabolite-
only spectrum without the MM contributions [117].
In such a spectrum, the short T1 components of
macromolecule resonances are saturated, whereas the
metabolite peaks having longer T1 relaxation times are
almost unaffected.
CONCLUSIONS
In the present paper we focused on an important
aspect of the acquisition of the neurochemical pro-
file, i.e., handling the signals of macromolecules. We
reviewed three main approaches of handling signals of
MM. Overall, it is well accepted that adding in vivo
measured MM spectrum in the quantification step will
improve the reliability and accuracy of metabolite con-
centrations, especially at high magnetic fields where
individual MM resonances are better resolved. Finally,
the choice of approach to be used will depend substan-
tially on the data under investigation and on the user
objectives.
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